1146162-54-0 Usage
Description
1H-Pyrazole, 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-[[2-(trimethylsilyl)ethoxy]methyl]is a complex chemical compound that features a pyrazole ring with unique substituents. This molecule is characterized by the presence of a tetramethyl dioxaborolane group, which is a boron-containing heterocycle, and a trimethylsilyl ethoxy group, which includes a silicon atom. Its intricate structure positions it as a potential reagent or intermediate in organic synthesis, particularly for the formation of carbon-carbon and carbon-heteroatom bonds.
Uses
1H-Pyrazole, 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-[[2-(trimethylsilyl)ethoxy]methyl]is used as a reagent or intermediate in Organic Synthesis for the formation of carbon-carbon and carbon-heteroatom bonds. Its specific applications and potential uses would be determined by its exact structural features and functional groups, necessitating further experimental studies to fully understand its behavior and capabilities in various chemical processes.
Check Digit Verification of cas no
The CAS Registry Mumber 1146162-54-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,4,6,1,6 and 2 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1146162-54:
(9*1)+(8*1)+(7*4)+(6*6)+(5*1)+(4*6)+(3*2)+(2*5)+(1*4)=130
130 % 10 = 0
So 1146162-54-0 is a valid CAS Registry Number.
1146162-54-0Relevant articles and documents
TGF Beta RECEPTOR ANTAGONISTS
-
Page/Page column 47; 48, (2018/02/24)
The invention relates generally to compounds that modulate the activity of TGFβR-1 and TGFβR-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
5, 7-SUBSTITUTED-IMIDAZO [1, 2-C] PYRIMIDINES AS INHIBITORS OF JAK KINASES
-
Page/Page column 161-162, (2011/11/01)
Compounds of Formula I: (Formula should be inserted here) and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3, R4, R5, R6, R7, X1 and X2 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
